Skip to contentH
Hepion Pharmaceuticals, Inc.
H
HEPAHepion Pharmaceuticals, Inc. Q1 2024 · 10-Q
Revenue$0.00$0.00— vs Q1 2023 Net Income-$2.85M-$2.85MN/M vs Q1 2023 EPS Diluted-$28.13-$28.13N/M vs Q1 2023 Operating Income-$5,182,317N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Hepion Pharmaceuticals, Inc. · CIK 1583771 · Engraved from SEC EDGAR
ended Mar 31, 2024 · filed May 21, 2024 · 51 d after period end